Table 2 Clinical, neuroimaging features and outcome of patients with neurological symptoms after vaccinating inactivated COVID-19 vaccine

Neurological symptoms, n (%)

 Unilateral numbness

18 (94.7)

 Headache at the initial presentation

10 (52.6)

 Headache during the course

17 (89.5)

 Unilateral weakness

9 (47.4)

 Nausea /vomiting

4 (21.1)

 Perioral numbness

3 (15.8)

Neurological deficits, n (%)

 Sensory deficits

15 (79)

 Motor deficits

10 (52.6)

 Tongue deviation

5 (26.3)

Time of neurological symptom after vaccination, mins (median, IQR)

55 (21,661)

Time to complete recovery

  < 24 h

0 (0)

 24–72 h

1 (5.3)

 72 h -1 week

3 (15.8)

 1–2 weeks

8 (42.1)

 2–4 weeks

2 (10.5)

  > 4 weeks

5 (26.3)

Brain imaging

 Initial CT brain with normal findings, n (%)

15 (78)

 Time from symptom onset to CT scan, hr, median (IQR)

6.04 (2.3,13.5)

 Initial MRI brain with normal findings, n (%), n (%)

19 (100)

 Time from symptom onset to MRI scan, hr, median (IQR)

2.56 (1.6, 7.5)

 Non-invasive vascular imaging (CTA/MRA), n (%)

19 (100)

  No vascular abnormality

16 (84.2)

  Dynamic angiographic change in luminal narrowing, n (%)

3 (15.8)

Outcomes

 NIHSS

  Initial, median (IQR)

1 (1,2.5)

  at 2-week, median (IQR)

0 (0,0)

  at 4-week, median (IQR)

0 (0,0.5)

 mRS

  Initial, median (IQR)

1 (0.5,2)

  at 2-week, median (IQR)

0 (0,1)

  at 4-week, median (IQR)

0 (0,1)